Preview Mode Links will not work in preview mode

Medscape InDiscussion: Schizophrenia

Oct 5, 2022

Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it.

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.



Schizophrenia Practice Essentials

The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity

Comprehensive Review of the Research Employing the Schizophrenia Cognition Rating Scale (SCoRS)

Using a Meta-cognitive Wisconsin Card Sorting Test to Measure Introspective Accuracy and Biases in Schizophrenia and Bipolar Disorder

Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches

Brain HQ

Training Engagement, Baseline Cognitive Functioning, and Cognitive Gains With Computerized Cognitive Training: A Cross-Diagnostic Study

Efficacy and Safety of the Novel Glycine Transporter Inhibitor BI 425809 Once Daily in Patients With Schizophrenia: A Double-Blind, Randomised, Placebo-Controlled Phase 2 Study

A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients With Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial KarXT

F46. The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1)

Cognitive Training and Supported Employment for Persons With Severe Mental Illness: One-Year Results From a Randomized Controlled Trial

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia

Why Treating Early, Treating Well, and Treating for Life Is Important in Schizophrenia

Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia

P515. Genomic Analyses of Schizophrenia and Bipolar Disorder Patients With Very Poor Outcomes

Challenges in Assessment of Daytime Sleepiness in Cognitively Impaired Populations Can Be Bypassed Through Use of Ecological Momentary Assessment

Evidence for Avolition in Bipolar Disorder?